Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients

Jiang,Nian-Xin; Ge,Jun-Wei; Xian,Yu-Qiong; Huang,Shao-Ying; Li,Yan-Song

doi:10.3892/br.2016.617

Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients

Authors:
- Nian-Xin Jiang
- Jun-Wei Ge
- Yu-Qiong Xian
- Shao-Ying Huang
- Yan-Song Li
View Affiliations

Affiliations: Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China
Published online on: February 26, 2016 https://doi.org/10.3892/br.2016.617
Pages: 453-458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The polymorphisms of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) are important genetic factors for warfarin dose determinations. The present study aimed to investigate the contribution of the CYP2C9 and VKORC1 genotypes to warfarin dose requirement in atrial fibrillation (AF) patients, and to evaluate the clinical application of a warfarin‑dosing algorithm. A total of 122 AF patients with a target international normalized ratio of 2.0 to 3.0 were included to determine the genotypes of CYP2C9 (rs1057910) and VKORC1 (rs9923231). A warfarin‑dosing algorithm was developed based on age, height, and the CYP2C9 and VKORC1 genotypes of AF patients. The results indicated that the mean warfarin daily dose requirement was lower in the CYP2C9*1/*3 genotype compared with those in the homozygous wild‑type CYP2C9*1/*1 patients (P<0.05), and was higher in patients with the VKORC1 AG and GG genotypes compared with those with the AA genotype (P<0.05). The multivariate regression model showed that age, height, and the CYP2C9 and VKORC1 genotypes were the best variables for estimating warfarin dose (R2=56.4%). A new warfarin‑dosing algorithm was developed and its validity was confirmed in a second cohort of AF patients. During the 50‑day follow‑up, 63.3% (19/30) of control group patients and 86.7% (26/30) of patients in the experimental group acquired the warfarin maintenance dose. Among all the patients who acquired the warfarin maintenance dose, the mean time elapse from initiation until warfarin maintenance dose was significantly less in the experimental group (25.8±1.7 day) compared to the control group (33.1±1.9 day) (P<0.05). There was significant linear correlation between predicted warfarin maintenance dose and actual dose (r=0.822, P<0.01). In conclusion, a new warfarin‑dosing algorithm was developed based on the CYP2C9 and VKORC1 genotypes, and it can shorten the time elapse from initiation until warfarin maintenance dose in AF patients with warfarin therapy.

View Figures

View References

1	Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A and Hylek E: The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126(Suppl 3): 204S–233S. 2004. View Article : Google Scholar : PubMed/NCBI
2	Hirsh J, Guyatt G, Albers GW and Schunemann HJ: Proceedings of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-based guidelines. Chest. 126(Suppl 3): 172S–696S. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lam MP and Cheung BM: The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol. 73:340–347. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hawes EM and Viera AJ: Anticoagulation: Monitoring of patients receiving anticoagulation. FP Essent. 422:24–30. 2014.PubMed/NCBI
5	No authors listed: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet. 343:499–503. 1994.PubMed/NCBI
6	Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP and Briët E: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333:11–17. 1995. View Article : Google Scholar : PubMed/NCBI
7	Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D and White RH: Warfarin Optimized Outpatient Follow-up Study Group: Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med. 118:511–520. 1993. View Article : Google Scholar : PubMed/NCBI
8	No authors listed: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 348:633–638. 1996. View Article : Google Scholar : PubMed/NCBI
9	Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J and Deykin D: Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119(Suppl 1): 8S–21S. 2001. View Article : Google Scholar : PubMed/NCBI
10	Takahashi H and Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 40:587–603. 2001. View Article : Google Scholar : PubMed/NCBI
11	Approves Updated Warfarin FDA (Coumadin) Prescribing information: New genetic information may help providers improve initial dosing estimates of the anticoagulant for individual patients. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.htmlAccessed. February 19–2009
12	Mazzaccara C, Conti V, Liguori R, Simeon V, Toriello M, Severini A, Perricone C, Meccariello A, Meccariello P, Vitale DF, et al: Warfarin anticoagulant therapy: A Southern Italy pharmacogenetics-based dosing model. PLoS One. 8:e715052013. View Article : Google Scholar : PubMed/NCBI
13	Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, et al: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 106:135–140. 2005. View Article : Google Scholar : PubMed/NCBI
14	Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H and Gak E: Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 95:205–211. 2006.PubMed/NCBI
15	Aithal GP, Day CP, Kesteven PJL and Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:717–719. 1999. View Article : Google Scholar : PubMed/NCBI
16	Ekladious SM, Issac MS, El-Atty Sharaf SA and Abou-Youssef HS: Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Mol Diagn Ther. 17:381–390. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li X, Liu R, Luo ZY, Yan H, Huang WH, Yin JY, Mao XY, Chen XP, Liu ZQ, Zhou HH, et al: Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics. 16:583–590. 2015. View Article : Google Scholar : PubMed/NCBI
18	Scibona P, Redal MA, Garfi LG, Arbelbide J, Argibay PF and Belloso WH: Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants. Genet Mol Res. 11:70–76. 2012. View Article : Google Scholar : PubMed/NCBI
19	Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, et al: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 93:700–705. 2005.PubMed/NCBI
20	Senoo K, Lane D and Lip GY: Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 44:281–290. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lip GY and Lane DA: Stroke prevention in atrial fibrillation: A systematic review. JAMA. 313:1950–1962. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhou SF, Zhou ZW and Huang M: Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 278:165–188. 2010. View Article : Google Scholar : PubMed/NCBI
23	Vogl S, Lutz RW, Schönfelder G and Lutz WK: CYP2C9 genotype vs. metabolic phenotype for individual drug dosing - a correlation analysis using flurbiprofen as probe drug. PLoS One. 10:e01204032015. View Article : Google Scholar : PubMed/NCBI
24	Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, Dong L and Jiang H: Warfarin dosage response related pharmacogenetics in Chinese population. PLoS One. 10:e01164632015. View Article : Google Scholar : PubMed/NCBI
25	Oldenburg J, Watzka M, Rost S and Müller CR: VKORC1: Molecular target of coumarins. J Thromb Haemost. 5(Suppl 1): 1–6. 2007. View Article : Google Scholar : PubMed/NCBI
26	Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, et al: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 427:537–541. 2004. View Article : Google Scholar : PubMed/NCBI
27	Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ and Mumford AD: Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost. 6:1663–1670. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yang L, Ge W, Yu F and Zhu H: Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res. 125:e159–e166. 2010. View Article : Google Scholar : PubMed/NCBI
29	Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK and Kamali F: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood. 106:2329–2333. 2005. View Article : Google Scholar : PubMed/NCBI